Clinical pharmacology is an academic discipline and research field that investigates the effects of drugs in humans, focusing on their pharmacokinetics, pharmacodynamics, efficacy, and safety. Its significance lies in translating basic pharmacological science into rational therapeutics, optimizing drug use, and improving patient outcomes.
Ontological type
Core Methods
Therapeutic Applications
Drug Development Role
Foundations of Clinical Pharmacology
1940 - 1961
PK/PD Integration and Mechanism
1962 - 1988
Model‑Informed Precision Pharmacology
1989 - 2023
Foundations of Clinical Pharmacology era
John H. Moyer [1] was active across Baylor College of Medicine [2] and the University of Pennsylvania [3] during the Foundations of Clinical Pharmacology era (1940–1961). His key contribution in this era was the 1953 paper Dibenzyline: Results of Therapy in Patients with Hypertension and a Comparison with Hexamethonium, 1-Hydrazinophthalazine and Semipurified Extracts of Veratrum [4], which provided a systematic, comparative evaluation of antihypertensive therapies and helped illustrate the move toward dose-aware treatment and safety monitoring. This work exemplified the empirical translation of laboratory pharmacology into bedside regimens, reinforcing measurement-driven dosing and the emergence of routine therapeutic drug monitoring under Moyer [1]. By linking the clinical settings of Baylor College of Medicine [2] and the University of Pennsylvania [3], Moyer's research helped institutionalize clinical pharmacology as a framework for standardized testing, monitoring, and safer prescribing in this era.
PK/PD Integration and Mechanism era
John R. Vane [1] conducted influential work across Yale University [3] and University of Cambridge [4] in this era. His key contributions include Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs [7], which linked drug action to a defined biochemical mechanism and anchored pharmacodynamics in therapeutic decision making for this era. David G. Shand [2], whose affiliations include Johns Hopkins University [5] and United States Military Academy [6], advanced clinical pharmacology through plasma and disposition studies such as Plasma propranolol levels in adults With observations in four children [8], establishing methods for concentration measurements across populations. The Disposition of Propranolol [9] and The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat [10] collectively showed how plasma binding and cross-species data shape half-lives and distribution volumes, underscoring the PK/PD linkage critical for dosing across adults, children, and organ-impaired patients.
Model‑Informed Precision Pharmacology era
Douglas G. Altman [1] is associated with the Institute of Cancer Research [3] and Stanford University [4] in this era. His key contributions include shaping reporting standards for in vivo studies through the ARRIVE guidelines [7], which improved study transparency and enabled more reliable synthesis of preclinical data for model-informed pharmacology. Michael Emerson [2] is associated with University College London [5] and Imperial College London [6] in this era. His contribution centers on advancing animal research reporting practices via the ARRIVE guidelines [7], a refinement that supported data streams crucial for exposure-response modeling and regulatory decision-making in the era.